Skip to main content
Erschienen in: Pathology & Oncology Research 4/2019

02.03.2018 | Original Article

Profiling of Germline Mutations in Major Hotspot Codons of TP53 Using PCR-RFLP

verfasst von: Srividya, B. H. Giridhar, S. Vishwanath, Anirban Chakraborty

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Tumor suppressor protein, TP53 also known as the “guardian of the genome” plays a key role in preventing malignant transformation. Almost 50% of human tumors carry mutations in this gene; in the remaining tumors, the TP53 network is functionally inoperative. The majority of TP53 mutations are missense mutations and more than 90% of the missense mutations affect specific codons in the DNA-binding domain, called “hotspot codons.” The present study was aimed at analyzing the germline mutation status of four hotspot codons in TP53 namely, codon 175, codon 245, codon 248 (within the DNA binding domain) and codon 72 (outside the DNA binding domain) in cancer cases encountered in a tertiary care hospital in South India by PCR-RFLP. The case-control study included 85–10 subjects respectively. The results of the study indicated that majority of the cancer cases did not harbor germline mutations in the four hot spot codons of TP53. The study further highlights the usefulness of PCR-RFLP as a simple and cost effective tool for checking gene mutations.
Literatur
1.
Zurück zum Zitat Chakraborty A, Uechi T, Kenmochi N (2011) Guarding the ‘translation apparatus’: defective ribosome biogenesis and the p53 signaling pathway. WIREs RNA 2:507–522CrossRef Chakraborty A, Uechi T, Kenmochi N (2011) Guarding the ‘translation apparatus’: defective ribosome biogenesis and the p53 signaling pathway. WIREs RNA 2:507–522CrossRef
2.
Zurück zum Zitat Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453–456CrossRef Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453–456CrossRef
3.
Zurück zum Zitat Zilfou J, Lowe S (2009) Tumor suppressive functions of p53. CSH Perspectives a001883 Zilfou J, Lowe S (2009) Tumor suppressive functions of p53. CSH Perspectives a001883
4.
Zurück zum Zitat Pecorino L (2012) Text book of molecular biology of cancer. Oxford University Press, USA Pecorino L (2012) Text book of molecular biology of cancer. Oxford University Press, USA
5.
Zurück zum Zitat Alex S, Varda R (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788–6793 Alex S, Varda R (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788–6793
6.
Zurück zum Zitat Hainaut P, Hollstein M (2000) P53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81–137CrossRef Hainaut P, Hollstein M (2000) P53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81–137CrossRef
7.
Zurück zum Zitat Matei C, Negura L, Liliac L, Negura A, Azoicai D (2012) Validation of PCR-RFLP techniques for the evaluation of codon 72 of p53 and CYP1A1 gene’s polymorphisms in relation ovarian cancer in Romanian population. Romanian J Morphol Embryol 53(1):47–54 Matei C, Negura L, Liliac L, Negura A, Azoicai D (2012) Validation of PCR-RFLP techniques for the evaluation of codon 72 of p53 and CYP1A1 gene’s polymorphisms in relation ovarian cancer in Romanian population. Romanian J Morphol Embryol 53(1):47–54
8.
Zurück zum Zitat Chen P, Lin S, Wang C, Chen Y, Chen T, Chang J (1993) “HotSpots” mutation analysis of p53 gene in gastro intestinal cancers by amplification of naturally occurring and artificially created restriction sites. Clin Chem 39:2186–2191PubMed Chen P, Lin S, Wang C, Chen Y, Chen T, Chang J (1993) “HotSpots” mutation analysis of p53 gene in gastro intestinal cancers by amplification of naturally occurring and artificially created restriction sites. Clin Chem 39:2186–2191PubMed
9.
Zurück zum Zitat Chittmittrapap S, Chieochansin T, Chaiteerakij R, Treeprasertsuk S, Klaikaew N, Tangkijvanich P, Komolmit P, Poovorawan Y (2013) Prevalence of aflatoxin induced P53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). Asian Pac J Cancer Prev 14(12):7675–7679CrossRef Chittmittrapap S, Chieochansin T, Chaiteerakij R, Treeprasertsuk S, Klaikaew N, Tangkijvanich P, Komolmit P, Poovorawan Y (2013) Prevalence of aflatoxin induced P53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). Asian Pac J Cancer Prev 14(12):7675–7679CrossRef
10.
Zurück zum Zitat Liming O, Chongtao G, Haizhen W, Suxia L, Huizhan Z (2009) PCR- RFLP to detect codon 248 mutation in exon 7 of p53 tumor suppressor gene. Biochem Mol Biol Educ 37:106–109CrossRef Liming O, Chongtao G, Haizhen W, Suxia L, Huizhan Z (2009) PCR- RFLP to detect codon 248 mutation in exon 7 of p53 tumor suppressor gene. Biochem Mol Biol Educ 37:106–109CrossRef
11.
Zurück zum Zitat Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SY40-transformed cells. Nature 278:261–263CrossRef Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SY40-transformed cells. Nature 278:261–263CrossRef
12.
Zurück zum Zitat Linzer DI, Levine AJ (1979) Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43–52CrossRef Linzer DI, Levine AJ (1979) Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43–52CrossRef
13.
Zurück zum Zitat Soussi T (2000) p53 Antibodies in the Sera of Patients with Various Types of Cancer: A Review. Cancer 60:1777–1788 Soussi T (2000) p53 Antibodies in the Sera of Patients with Various Types of Cancer: A Review. Cancer 60:1777–1788
14.
Zurück zum Zitat Nigro JM, Baker SJ, Preisinger AC, Jessup J, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilees P, Glover T, Collins FS, Weston A, Modali R, Harris C, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708CrossRef Nigro JM, Baker SJ, Preisinger AC, Jessup J, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilees P, Glover T, Collins FS, Weston A, Modali R, Harris C, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708CrossRef
15.
Zurück zum Zitat Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, Miliaras D, Pantazis K, Constantinides TC, Kotsis A, Bontis I (2004) p53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 13:277–280CrossRef Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, Miliaras D, Pantazis K, Constantinides TC, Kotsis A, Bontis I (2004) p53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 13:277–280CrossRef
16.
Zurück zum Zitat Freed-Pastor W, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26:1268–1286CrossRef Freed-Pastor W, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26:1268–1286CrossRef
17.
Zurück zum Zitat Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9:862–873CrossRef Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9:862–873CrossRef
Metadaten
Titel
Profiling of Germline Mutations in Major Hotspot Codons of TP53 Using PCR-RFLP
verfasst von
Srividya
B. H. Giridhar
S. Vishwanath
Anirban Chakraborty
Publikationsdatum
02.03.2018
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0394-8

Weitere Artikel der Ausgabe 4/2019

Pathology & Oncology Research 4/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.